CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
COMPUGEN LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026
$1.97+0.01 (+0.51%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 5.2
- Dividend yield
- –
Compugen statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Compugen | Industry median |
|---|---|---|
| Market Cap | $186.27M | $164.85M |
| Enterprise Value | $86.39M | $87.06M |
| PE Ratio | 5.18 | 19.63 |
| PS Ratio | 2.56 | 3.60 |
| PB Ratio | 1.81 | 2.03 |
| P/TBV Ratio | 1.81 | 2.31 |
| P/FCF Ratio | 5.95 | 17.44 |
| P/OCF Ratio | 5.89 | 13.32 |
Enterprise value
| Measure | Compugen | Industry median |
|---|---|---|
| EV / Sales | 1.19 | 2.43 |
| EV / EBITDA | 2.76 | 14.69 |
| EV / EBIT | 2.76 | 18.47 |
| EV / FCF | 2.76 | 20.97 |
Income (trailing twelve months)
| Measure | Compugen | Industry median |
|---|---|---|
| Revenue | $72.76M | $57.94M |
| Gross Profit | $63.51M | $90.47M |
| Operating Income | $31.33M | -$21.44M |
| Pretax Income | $35.40M | -$14.45M |
| Net Income | $35.34M | -$22.46M |
| EBITDA | $31.33M | -$16.91M |
| EPS (Diluted) | $0.38 | -$0.83 |
Margins
| Measure | Compugen | Industry median |
|---|---|---|
| Gross Margin | 87.3% | 52.3% |
| Operating Margin | 43.1% | -44.5% |
| Pretax Margin | 48.6% | -13.0% |
| Profit Margin | 48.6% | -39.2% |
| EBITDA Margin | 43.1% | -31.3% |
| FCF Margin | 43.1% | -8.85% |
Returns
| Measure | Compugen | Industry median |
|---|---|---|
| Return on Equity (ROE) | 44.8% | -53.1% |
| Return on Assets (ROA) | 26.0% | -41.0% |
| Return on Invested Capital (ROIC) | 393.3% | -32.0% |
| Return on Capital Employed (ROCE) | 23.4% | -37.8% |
Growth
| Measure | Compugen | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 161.1% | 6.01% |
| FCF Growth (YoY) | -36.7% | 2.34% |
| Revenue Growth (3Y CAGR) | 113.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 105.2% | 6.42% |
Balance sheet
| Measure | Compugen | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $99.88M | $62.42M |
| Net Cash (Debt) | $99.88M | $15.68M |
| Net Cash Per Share | $1.06 | $0.66 |
| Equity (Book Value) | $102.73M | $48.79M |
| Book Value Per Share | $1.09 | $1.36 |
| Tangible Book Value | $102.73M | $23.06M |
| Working Capital | $125.45M | $75.77M |
Financial position
| Measure | Compugen | Industry median |
|---|---|---|
| Current Ratio | 6.56 | 3.30 |
| Quick Ratio | 4.43 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Compugen | Industry median |
|---|---|---|
| Operating Cash Flow | $31.63M | -$12.35M |
| Capital Expenditures | -$306.00K | -$1.06M |
| Free Cash Flow | $31.33M | -$20.28M |
| FCF Per Share | $0.33 | -$0.42 |
Efficiency
| Measure | Compugen | Industry median |
|---|---|---|
| Asset Turnover | 0.54 | 0.38 |
| Revenue Per Employee | $36.38M | $398.96K |
| Profits Per Employee | $17.67M | -$703.34K |
| Employee Count | 2 | 74 |
Dividends and yields
| Measure | Compugen | Industry median |
|---|---|---|
| Earnings Yield | 19.0% | -22.7% |
| FCF Yield | 16.8% | -9.07% |
| Buyback Yield | -5.66% | -0.73% |
| Shareholder Yield | -5.66% | 0.00% |
Shares
| Measure | Compugen | Industry median |
|---|---|---|
| Shares Outstanding | 94,553,200 | 58,179,650 |
| Shares Change (YoY) | 4.79% | 11.1% |
| Float | 94,146,800 | 49,173,100 |
| Shares Held by Insiders | 0.43% | 11.6% |
Taxes
| Measure | Compugen | Industry median |
|---|---|---|
| Income Tax | $54.00K | $91.50K |
| Effective Tax Rate | 0.15% | 20.6% |
Scores
| Measure | Compugen | Industry median |
|---|---|---|
| Graham Number | $3.05 | $17.36 |
| Graham Upside | 54.7% | -43.6% |
| Altman Z-Score | 0.11 | -0.24 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Compugen's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.